Halitosis originates from an oral or a non-oral source. It is caused by volatile molecules, which are developed due to pathological or non-pathological reasons. These volatile compounds are aromatic compounds, sulphur compounds, short-chain fatty acids, nitrogen-containing compounds, amines, aliphatic compounds, alcohols or phenyl compounds, and ketones.

Various causes of halitosis include cancer of the larynx, nasopharyngeal abscess, and lower respiratory tract infections such as asthma, bronchiectasis, chronic bronchitis, bronchiectasis, lung abscess, cystic fibrosis, interstitial lung diseases, and pneumonia. According to the International Journal of Oral Science 2012 study, around 10% of the oral malodor cases originate from the ears, nose and throat region, and 3% of it occur due to tonsils.

Market Dynamics

Increasing consumption of tobacco and alcohol, medical condition such as tonsils and inflammation of nose, throat or sinuses and metabolic diseases are the major factors driving the halitosis treatment market growth. According to the National Center for Biotechnology Information (NCBI) 2013 study, halitosis is very common and affects around 50% of the general population around the world.

Although halitosis has multifactorial origins, around 90% cases occur due to oral cavity such as poor oral hygiene, tongue coat, periodontal disease, unclean dentures, food impaction, oral carcinomas, faulty restorations, and throat infections. Treatment of halitosis is very important, as it can cause serious conditions such as stress. According to the Bad Breath Institute 2018 study, people with halitosis are 60% more likely to suffer from stress, while 57% of bad breath sufferers report feelings of depression due to their condition. However, lack of awareness among the under developed regions can confine the halitosis treatment market growth.

Key features of the study:

• This report provides in-depth analysis of the halitosis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global halitosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Abbott Laboratories, AstraZeneca Plc, Colgate-Palmolive Company, Dr. Harold Katz, Listerine, and Rowpar Pharmaceuticals
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global halitosis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for halitosis treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• Global Halitosis Treatment Market, By Type:
• Pathological
• Non-pathological
• Global Halitosis Treatment Market, By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Global Halitosis Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Africa
• By Country:
• South Africa
• Central Africa
• North Africa
• By Type:
• Pathological
• Non-pathological
• By Treatment:
• Antacids
• Antiseptics
• Antiplaque
• Others
• Company Profiles
• Abbott Laboratories*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• AstraZeneca Plc
• Colgate-Palmolive Company
• Harold Katz
• Listerine
• Rowpar Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.